Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTY720 Safety and Tolerability in Relapsing MS
NCT01127750Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Started May 2010; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01127750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01127750.